ILMN
Price
$144.03
Change
-$0.00 (-0.00%)
Updated
Oct 28 closing price
6 days until earnings call
PACB
Price
$1.84
Change
-$0.00 (-0.00%)
Updated
Oct 28 closing price
9 days until earnings call
Ad is loading...

ILMN vs PACB

Header iconILMN vs PACB Comparison
Open Charts ILMN vs PACBBanner chart's image
Illumina
Price$144.03
Change-$0.00 (-0.00%)
Volume$853.61K
CapitalizationN/A
Pacific Biosciences of California
Price$1.84
Change-$0.00 (-0.00%)
Volume$6.22M
CapitalizationN/A
View a ticker or compare two or three
ILMN vs PACB Comparison Chart
Loading...
ILMN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PACB
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
ILMN vs. PACB commentary
Oct 30, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ILMN is a Buy and PACB is a Buy.

COMPARISON
Comparison
Oct 30, 2024
Stock price -- (ILMN: $143.97 vs. PACB: $1.84)
Brand notoriety: ILMN: Notable vs. PACB: Not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: ILMN: 47% vs. PACB: 78%
Market capitalization -- ILMN: $21.09B vs. PACB: $976.68M
ILMN [@Medical Specialties] is valued at $21.09B. PACB’s [@Medical Specialties] market capitalization is $976.68M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $7.97B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ILMN’s FA Score shows that 1 FA rating(s) are green whilePACB’s FA Score has 0 green FA rating(s).

  • ILMN’s FA Score: 1 green, 4 red.
  • PACB’s FA Score: 0 green, 5 red.
According to our system of comparison, ILMN is a better buy in the long-term than PACB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ILMN’s TA Score shows that 3 TA indicator(s) are bullish while PACB’s TA Score has 3 bullish TA indicator(s).

  • ILMN’s TA Score: 3 bullish, 5 bearish.
  • PACB’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, PACB is a better buy in the short-term than ILMN.

Price Growth

ILMN (@Medical Specialties) experienced а -0.85% price change this week, while PACB (@Medical Specialties) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -2.01%. For the same industry, the average monthly price growth was +3.93%, and the average quarterly price growth was -2.96%.

Reported Earning Dates

ILMN is expected to report earnings on Feb 06, 2025.

PACB is expected to report earnings on Feb 13, 2025.

Industries' Descriptions

@Medical Specialties (-2.01% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ILMN($21.1B) has a higher market cap than PACB($977M). ILMN YTD gains are higher at: 6.373 vs. PACB (-81.244). PACB has higher annual earnings (EBITDA): -277.28M vs. ILMN (-608M). ILMN has more cash in the bank: 1.05B vs. PACB (631M). PACB has less debt than ILMN: PACB (934M) vs ILMN (2.26B). ILMN has higher revenues than PACB: ILMN (4.5B) vs PACB (201M).
ILMNPACBILMN / PACB
Capitalization21.1B977M2,160%
EBITDA-608M-277.28M219%
Gain YTD6.373-81.244-8%
P/E Ratio49.50N/A-
Revenue4.5B201M2,241%
Total Cash1.05B631M167%
Total Debt2.26B934M242%
FUNDAMENTALS RATINGS
ILMN vs PACB: Fundamental Ratings
ILMN
PACB
OUTLOOK RATING
1..100
6768
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
99
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
1361
P/E GROWTH RATING
1..100
9384
SEASONALITY SCORE
1..100
n/a95

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ILMN's Valuation (75) in the Biotechnology industry is in the same range as PACB (99). This means that ILMN’s stock grew similarly to PACB’s over the last 12 months.

ILMN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PACB (100). This means that ILMN’s stock grew similarly to PACB’s over the last 12 months.

ILMN's SMR Rating (98) in the Biotechnology industry is in the same range as PACB (98). This means that ILMN’s stock grew similarly to PACB’s over the last 12 months.

ILMN's Price Growth Rating (13) in the Biotechnology industry is somewhat better than the same rating for PACB (61). This means that ILMN’s stock grew somewhat faster than PACB’s over the last 12 months.

PACB's P/E Growth Rating (84) in the Biotechnology industry is in the same range as ILMN (93). This means that PACB’s stock grew similarly to ILMN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ILMNPACB
RSI
ODDS (%)
Bearish Trend 2 days ago
74%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 6 days ago
80%
Bearish Trend 6 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 2 days ago
89%
Aroon
ODDS (%)
Bullish Trend 2 days ago
64%
N/A
View a ticker or compare two or three
Ad is loading...
ILMN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PACB
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME22.732.16
+10.50%
GameStop Corp
BTC.X69907.7600001978.460900
+2.91%
Bitcoin cryptocurrency
AAPL233.401.99
+0.86%
Apple
SPY580.831.79
+0.31%
SPDR® S&P 500® ETF Trust
TSLA262.51-6.68
-2.48%
Tesla

ILMN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ILMN has been loosely correlated with RVTY. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ILMN jumps, then RVTY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ILMN
1D Price
Change %
ILMN100%
+1.42%
RVTY - ILMN
48%
Loosely correlated
+1.00%
BIO - ILMN
48%
Loosely correlated
+2.61%
VCYT - ILMN
46%
Loosely correlated
+3.30%
TWST - ILMN
43%
Loosely correlated
+4.73%
AZTA - ILMN
43%
Loosely correlated
+2.54%
More

PACB and

Correlation & Price change

A.I.dvisor indicates that over the last year, PACB has been loosely correlated with MASI. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if PACB jumps, then MASI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PACB
1D Price
Change %
PACB100%
+3.95%
MASI - PACB
58%
Loosely correlated
+0.99%
AZTA - PACB
48%
Loosely correlated
+2.54%
TWST - PACB
43%
Loosely correlated
+4.73%
MASS - PACB
41%
Loosely correlated
+3.04%
VCYT - PACB
40%
Loosely correlated
+3.30%
More